Biomerica (BMRA) said Thursday that its inFoods Irritable Bowel Syndrome test will be marketed by Henry Schein (HSIC) in the US, with the exception of New York State, as part a marketing services arrangement between the two companies.
Henry Schein will market the test to primary care and gastroenterology specialty practices, Biomerica said.
Financial details of the agreement were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.